Decreased macrophage content per lesion area in atherosclerotic lesions from ABCA1 KO→LDLr KO mice. by Bart Lammers (302835)

C4BP binding to <i>N</i>. <i>gonorrhoeae</i> is necessary and sufficient for the serum-mediated decrease in bacterial association with neutrophils. by Lacie M. Werner (14710419)

Fig 7 - by P. R. Hut (12152350)

Mitotic catastrophe is dependent on CRM-1 dysregulation. by Zachary J. Hough (20840430)

Confocal images presenting the phenotypes of S100A6-immunopositive cells in the ARH. by Katarzyna Bartkowska (453261)

Confocal images presenting the phenotypes of S100A6-immunopositive cells in the SVZ. by Katarzyna Bartkowska (453261)

Expression of glyoxalase-I is reduced in cirrhotic livers: A possible mechanism in the development of cirrhosis by Marcus Hollenbach (376231)

“…Blunting of the Glo-I activity decrease the amount of fibrosis in established cirrhosis and constitutes a novel target for antifibrotic therapy.…”

Results of western blots showing the protein levels in different brain structures. by Katarzyna Bartkowska (453261)

S1/2^-/- mice display novelty induced hyperactivity, decreased anxiety and exploratory behavior and working memory disturbances. by Paul C. Baier (650225)

“…I-J) S1/2^-/- mice showed increased number of working errors searching for a hidden platform on the first (I) (E_genotype F_(1,55) = 3.93; p = 0.0524; I_{genotype×time} F_(3,165) = 2.68; p = 0.0486) and the second (J) day of experiment (E_genotype F_(1,55) = 9.05; p = 0.0044) and I_{genotype×time} F_(5,275) = 2.34; p = 0.0422). …”

CDK2/Speedy A localization in <i>Cdk2</i>^{<i>−/−</i>} and <i>Speedy A</i>^{<i>−/−</i>} spermatocytes. by Nathan Palmer (264897)

“…Percentages of mid-pachytene–stage nuclei with at least one telomere showing a decrease in telomeric Speedy A intensity of ≥50% (as compared to the average telomeric Speedy A intensity for that cell) are quantified in panel I. …”

Example of K^trans decrease during therapy. by Jean-Philip Daniel Weber (12213395)

“…<p>NSCLC of the left upper lobe showing a clear decrease of K^trans from baseline (left) to first follow-up after 1 week of checkpoint inhibition by Erlotinib and Bevacizumab.…”

Levels of intermediates involved in L-tryptophan biosynthesis detected in FB-04, FB-04(<i>Δpta</i>), and FB-04(<i>pta</i>1). by Lina Liu (227490)

Subjects:

Quantity of <i>Salmonella</i> modeled using multilevel mixed linear regression. by Naomi Ohta (735090)

Diet composition and nutritional values. by Taynara Aparecida Vieira (16401726)

“…The HSF group exhibited obesity (HSF 8.77 ± 2.64 <i><i>vs</i></i> C 3.09 ± 1.02, <i>p = </i>0.007), dyslipidemia (HSF 94.4 ± 19.1 <i><i>vs</i></i> C 26.7 ± 5.2, <i><i>p < </i></i>0.001), hypertension (HSF 141 ± 8 <i><i>vs</i></i> C 120 ± 4, <i>p = </i>0.001), insulin resistance (HSF 6.91 ± 1.38 <i><i>vs</i></i> C 2.47 ± 1.01, <i><i>p < </i></i>0.001), cardiac remodeling and dysfunction, cardiac inflammation, decreased metalloproteinase-2 (MMP-2) (HSF 0.43 ± 0.09 <i><i>vs</i></i> C 0.71 ± 0.07, <i>p = </i>0.009) and increased type III collagen (HSF 1.32 ± 0.27 <i><i>vs</i></i> C 1.00 ± 0.18, <i>p = </i>0.038). …”

Nutritional and metabolic analysis. by Taynara Aparecida Vieira (16401726)

“…The HSF group exhibited obesity (HSF 8.77 ± 2.64 <i><i>vs</i></i> C 3.09 ± 1.02, <i>p = </i>0.007), dyslipidemia (HSF 94.4 ± 19.1 <i><i>vs</i></i> C 26.7 ± 5.2, <i><i>p < </i></i>0.001), hypertension (HSF 141 ± 8 <i><i>vs</i></i> C 120 ± 4, <i>p = </i>0.001), insulin resistance (HSF 6.91 ± 1.38 <i><i>vs</i></i> C 2.47 ± 1.01, <i><i>p < </i></i>0.001), cardiac remodeling and dysfunction, cardiac inflammation, decreased metalloproteinase-2 (MMP-2) (HSF 0.43 ± 0.09 <i><i>vs</i></i> C 0.71 ± 0.07, <i>p = </i>0.009) and increased type III collagen (HSF 1.32 ± 0.27 <i><i>vs</i></i> C 1.00 ± 0.18, <i>p = </i>0.038). …”

Cardiovascular parameters. by Taynara Aparecida Vieira (16401726)

“…The HSF group exhibited obesity (HSF 8.77 ± 2.64 <i><i>vs</i></i> C 3.09 ± 1.02, <i>p = </i>0.007), dyslipidemia (HSF 94.4 ± 19.1 <i><i>vs</i></i> C 26.7 ± 5.2, <i><i>p < </i></i>0.001), hypertension (HSF 141 ± 8 <i><i>vs</i></i> C 120 ± 4, <i>p = </i>0.001), insulin resistance (HSF 6.91 ± 1.38 <i><i>vs</i></i> C 2.47 ± 1.01, <i><i>p < </i></i>0.001), cardiac remodeling and dysfunction, cardiac inflammation, decreased metalloproteinase-2 (MMP-2) (HSF 0.43 ± 0.09 <i><i>vs</i></i> C 0.71 ± 0.07, <i>p = </i>0.009) and increased type III collagen (HSF 1.32 ± 0.27 <i><i>vs</i></i> C 1.00 ± 0.18, <i>p = </i>0.038). …”

Fig 3 - by Qasim Ali (802840)

Fig 2 - by Qasim Ali (802840)

Fig 5 - by Qasim Ali (802840)

Fig 6 - by Qasim Ali (802840)